和铂医药-B(02142.HK)：根据与Spruce订立的授权及合作协议行使认股权证

Core Viewpoint - HBM Alpha Therapeutics, a biotech company incubated by the company, has entered into a licensing and collaboration agreement with Spruce Biosciences to advance novel CRH-targeted therapies for various diseases [1] Group 1: Agreement Details - The agreement allows HBMAT and its affiliates to obtain warrants related to minority equity to purchase common stock of Spruce [1] - The company and HBMAT will exercise the warrants on January 19, 2026 [1] Group 2: Equity Holdings - Upon exercising the warrants, the company will hold approximately 3.8% of Spruce's outstanding shares and about 3.1% of Spruce's fully diluted shares [1]